The Good Governance Index evaluates the performance of a health facility across 20 indicators in areas such as client satisfaction, availability of essential medicines and laboratory tests, staffing levels, and emergency response times. Based on weighted scores across the indicators, the health facility achieved a total Good Governance Index score of 100 out of 100.
The Good Governance Index evaluates the performance of a health facility across 20 indicators in areas such as client satisfaction, availability of essential medicines and laboratory tests, staffing levels, and emergency response times. Based on weighted scores across the indicators, the health facility achieved a total Good Governance Index score of 100 out of 100.
The Good Governance Index evaluates the performance of a health facility across 20 indicators in areas such as client satisfaction, availability of essential medicines and laboratory tests, staffing levels, and emergency response times. Based on weighted scores across the indicators, the health facility achieved a total Good Governance Index score of 100 out of 100.
Weight(W) Client Satisfaction Rate 18 11.9 Proportion of patients receiving 5 3.05 comprehensive information on their health states and treatment Proportion of patients receiving 5 3.5 all prescribed medicine Proportion of availability of 25 24.5 essential medicine out of the health facility essential list of drug Proportion of patients 3 complaints resolved Rate of budget utilization 2 Average Lot Quality Assurance 2 1.83 Sampling score (LQA Bed Occupancy Rate 5 3 Proportion of available 15 laboratory tests out of the total (85 tests) as per MOH standard Proportion of patients who 5 received all ordered laboratory or imaging services Staff attrition rate/ 3 3 Absenteeism Major surgery per surgeon/ 4 3.8 Health Workforce Productivity Average length of stay 3 3 Proportion of emergency 3 2.49 patients triaged within 5 minutes Proportion of patients staying 2 2 in emergency room for more than 24 hours Good Governance Index 100
Efficacy and Safety of Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation, A Network Analysis Edit